Abstract
We investigated the suppressive effects of 3-O-methylquercetin 5,7,3′,4′-O-tetraacetate (QMTA), a more-potent phosphodiesterase (PDE)3/4 inhibitor than quercetin 3-O-methyl ether (3-MQ), which has been reported to have the potential for treating asthma, against ovalbumin (OVA)-induced airway hyperresponsiveness (AHR). The IC50 value of QMTA for PDE3 was significantly less than that for PDE4. According to the Lineweaver-Burk analysis, QMTA (1 - 10 μM) competitively inhibited PDE3 and PDE4 activities. The Ki values were 0.9 ± 0.3 (n = 5) and 3.9 ± 0.5 (n = 5) µM, respectively, which significantly differed from each other, suggesting that QMTA has higher affinity for PDE3 than for PDE4. QMTA (3 - 10 μM) concentration-dependently relaxed the baseline level, and significantly inhibited cumulative OVA (10 - 100 μg/mL)-induced contractions in isolated sensitized guinea pig trachealis suggesting that QMTA has bronchodilator and inhibiting effects on mast cell degranulation. After the secondary challenge, the AHR was measured in unrestrained OVA-sensitized mice, with nebulized methacholine (MCh, 6.25 - 50 mg/mL), by barometric plethysmography using a whole-body plethysmograph. In the present results, QMTA (3 - 10 μmol/kg, i. p.) dose-dependently attenuated the enhanced pause (Penh) value induced by MCh (25 - 50 mg/mL). QMTA (3 - 10 μmol/kg, i. p.) also significantly inhibited total inflammatory cells, macrophages, neutrophils, lymphocytes, and eosinophils in BALF after determination of Penh values. It also significantly suppressed the release of interleukin (IL)-2, IL-4, IL-5, IFN-γ, and TNF-α, with the exception that 3 μmol/kg QMTA did not suppress the releases of IL-5. QMTA even at 1 μmol/kg significantly inhibited eosinophils, IL-2, and TNF-α. In conclusion, our results strongly suggest that QMTA has greater potential than 3-MQ for the treatment of asthma.
Abbreviations
AHR:airway hyperresponsiveness
BALF:bronchoalveolar lavage fluid
CBA:cytometric bead array
IFN-γ:interferon-γ
IL:interleukin
OVA:ovalbumin
PDE:phosphodiesterase
Penh:enhanced pause
QMTA:3-O-methylquercetin 5,7,3′,4′-O-tetraacetate
TNF-α:tumor necrosis factor-α
Key words
3-O-methylquercetin 5,7,3′,4′-O-tetraacetate - phosphodiesterase inhibitor - ovalbumin - inflammatory cells - cytokines - asthma
References
-
1
Lee M E, Markowitz J, Lee J O, Lee H.
Crystal structure of phosphodiesterase 4D and inhibitor complex (1).
FEBS Lett.
2002;
530
53-8.
-
2
de Boer J, Philpott A J, van Amsterdam R G, Shahid M, Zaagsma J, Nicholson C D.
Human bronchial cyclic nucleotide phosphodiesterase isoenzymes: biochemical and pharmacological analysis using selective inhibitors.
Br J Pharmacol.
1992;
106
1028-34.
-
3
Silver P J, Hamel L T, Perrone M H, Bentley R G, Bushover C R, Evans D B.
Differential pharmacologic sensitivity of cyclic nucleotide phosphodiesterase isozymes isolated from cardiac muscle, arterial and airway smooth muscle.
Eur J Pharmacol.
1988;
150
85-94.
-
4
Ko W C, Chen M C, Wang S H, Lai Y H, Chen J H, Lin C N.
3-O-Methylquercetin more selectively inhibits phosphodiesterase subtype 3.
Planta Med.
2003;
69
310-5.
-
5
Underwood D C, Kotzer C J, Bochnowicz S, Osborn R R, Luttmann M A, Hay D W. et al .
Comparison of phosphodiesterase III, IV and dual III/IV inhibitors on bronchospasm and pulmonary eosinophil influx in guinea pigs.
J Pharmacol Exp Ther.
1994;
270
250-9.
-
6
Chiu N Y, Chang K H.
The illustrated medicinal plants of Taiwan. 5.
Taipei: Southern Materials.
Center;
1998
135-6.
-
7
Jiang J S, Shih C M, Wang S H, Chen T T, Lin C N, Ko W C.
Mechanisms of suppression of nitric oxide production by 3-O-methylquercetin in RAW 264.7 cells.
J Ethnopharmacol.
2006;
103
281-7.
-
8
Ko W C, Shih C M, Chen M C, Lai Y H, Chen J H, Chen C M. et al .
Suppressive effects of 3-O-methylquercetin on ovalbumin-induced airway hyperresponsiveness.
Planta Med.
2004;
70
1123-7.
-
9
Ferte J, Kuhnel J M, Chapuis G, Rolland Y, Lewin G, Schwaller M A.
Flavonoid-related modulators of multidrug resistance: synthesis, pharmacological activity, and structure-activity relationships.
J Med Chem.
1999;
42
478-89.
-
10
Lin C N, Lu C M, Lin H C, Ko F N, Teng C M.
Novel antiplatelet naphthalene from Rhamnus nakaharai
.
J Nat Prod.
1995;
58
1934-40.
-
11
Kanehiro A, Ikemura T, Makela M J, Lahn M, Joetham A, Dakhama A. et al .
Inhibition of phosphodiesterase 4 attenuates airway hyperresponsiveness and airway inflammation in a model of secondary allergen challenge.
Am J Respir Crit Care Med.
2001;
163
173-84.
-
12
Hamelmann E, Schwarze J, Takeda K, Oshiba A, Larsen G L, Irvin C G. et al .
Noninvasive measurement of airway responsiveness in allergic mice using barometric plethysmography.
Am J Respir Crit Care Med.
1997;
156
766-75.
-
13
Winterrowd G E, Chin J E.
Flow cytometric detection of antigen-specific cytokine responses in lung T cells in a murine model of pulmonary inflammation.
J Immunol Methods.
1999;
226
105-18.
-
14
Thompson W J, Appleman M M.
Multiple cyclic nucleotide phosphodiesterase activities from rat brain.
Biochemistry.
1971;
10
311-6.
-
15
Ahn H S, Crim W, Romano M, Sybertz E, Pitts B.
Effects of selective inhibitors on cyclic nucleotide phosphodiesterases of rabbit aorta.
Biochem Pharmacol.
1989;
38
3331-9.
-
16
Podzuweit T, Nennstiel P, Muller A.
Isozyme selective inhibition of cGMP-stimulated cyclic nucleotide phosphodiesterases by erythro-9-(2-hydroxy-3-nonyl) adenine.
Cell Signal.
1995;
7
733-8.
-
17
Harrison S A, Reifsnyder D H, Gallis B, Cadd G G, Beavo J A.
Isolation and characterization of bovine cardiac muscle cGMP-inhibited phosphodiesterase: a receptor for new cardiotonic drugs.
Mol Pharmacol.
1986;
29
506-14.
-
18
Reeves M L, Leigh B K, England P J.
The identification of a new cyclic nucleotide phosphodiesterase activity in human and guinea-pig cardiac ventricle. Implications for the mechanism of action of selective phosphodiesterase inhibitors.
Biochem J.
1987;
241
535-41.
-
19
Gillespie P G, Beavo J A.
Inhibition and stimulation of photoreceptor phosphodiesterases by dipyridamole and M&B 22,948.
Mol Pharmacol.
1989;
36
773-81.
-
20
Bradford M M.
A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.
Anal Biochem.
1976;
72
248-54.
-
21
Tsien R W.
Calcium channels in excitable cell membranes.
Annu Rev Physiol.
1983;
45
341-58.
-
22
Busse W W, Lemanske RF J r.
Asthma.
N Engl J Med.
2001;
344
350-62.
-
23
Revets H, Pynaert G, Grooten J, De Baetselier P.
Lipoprotein I, a TLR2/4 ligand modulates Th2-driven allergic immune responses.
J Immunol.
2005;
174
1097-103.
-
24
Taube C, Duez C, Cui Z H, Takeda K, Rha Y H, Park J W. et al .
The role of IL-13 in established allergic airway disease.
J Immunol.
2002;
169
6482-9.
-
25 Tucker J, Fanta C H. Integrative inflammation pharmacology: asthma. In: Golan DE, Tashjian Jr AH, Armstrong EJ, Galanter JM, Armstrong AW, Arnaout RA et al., editors Principles of pharmacology-the pathophysiologic basis of drug therapy. Philadephia; Lippincott Williams & Wilkins 2005: 695-705.
-
26
Vargaftig B B, Singer M.
Leukotrienes mediate murine bronchopulmonary hyperreactivity, inflammation, and part of mucosal metaplasia and tissue injury induced by recombinant murine interleukin-13.
Am J Respir Cell Mol Biol.
2003;
28
410-9.
-
27
Murphy A W, Platts-Mills T AE.
Drug used in asthma and obstructive lung disease. In: Brody TM, Larner J, Minneman KP, editors. Human pharmacology - molecular to clinical. St.
Louis:.
Mosby;
1998
797-825.
-
28
Groundwater P W, Solomons K R, Drewe J A, Munawar M A.
Protein tyrosine kinase inhibitors.
Prog Med Chem.
1996;
33
233-329.
-
29
Giembycz M A.
Phosphodiesterase 4 inhibitors and the treatment of asthma: Where are we now and where do we go from here?.
Drugs.
2000;
59
193-212.
-
30
Fan C K.
Phosphodiesterase inhibitors in airways disease.
Eur J Pharmacol.
2006;
533
110-7.
Prof. Dr. Wun-Chang Ko
Graduate Institute of Pharmacology
College of Medicine
Taipei Medical University
250 Wu-Hsing St.
Taipei 110
Taiwan
R.O.C.
Fax: +886-2-2377-7639
Email: wc_ko@tmu.edu.tw